Clinical Trial Update: Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 trial evaluating MT-3995 at a low dose in patients with diabetic nephropathy, focusing on safety, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Nephropathy

Drugs mentioned

• MT-3995

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Diabetic Nephropathy | Phase 1, Phase 2 | Status: COMPLETED